MK-0429 Inhibitor

Name: MK-0429 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5755193
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755193

MK-0429 is an orally active, selective, and nonpeptide antagonist of alphavbeta3 integrin (IC50: 80nM). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

MK-0429, Inhibitor

Full Product Name

MK-0429

Product Gene Name

MK-0429, inhibitor

Product Synonym Names

L-000845704

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

439.51

Solubility

DMSO: 250mg/mL (568.82mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C23H29N5O4

SMILES

O=C1N([C@H](C2=CC=C(OC)N=C2)CC(O)=O)CCN1CCCC3=NC4=C(C=C3)CCCN4

CAS Number

227963-15-7

Target & IC50

alphavbeta3 integrin: ic50 80nM

In Vitro

MK-0429 is safe and efficacious in obviously reducing melanoma metastasis in the lungs. MK-0429 (100 or 300mg/kg, p.o., twice daily b.i.d., 2 weeks) decreases metastatic tumor colony formation and area in the lungs [1].

Product Categories/Family for MK-0429, inhibitor

Cytoskeletal Signaling

Product References and Citations for MK-0429, inhibitor

Hutchinson JH, et al. Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment,of osteoporosis. J Med Chem. 2003 Oct 23;46(22):4790-8.
Hutchinson JH, et al. Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment,of osteoporosis. J Med Chem. 2003 Oct 23;46(22):4790-8.
Pickarski M, et al. Orally active alphavbeta3 integrin inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep. 2015 Jun;33(6):2737-45.
Pickarski M, et al. Orally active alphavbeta3 integrin inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep. 2015 Jun;33(6):2737-45.

Other Notes

Small volumes of MK-0429, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for MK-0429 purchase

MBS5755193 is an inhibitor targeting MK-0429.